

# UBS (CH) Institutional Fund – Equities Switzerland Passive Large II I-X

# Portrait

- Regulation / Supervision: CISA / FINMA (funds for qualified investors)
- Authorised investors: pension funds, insurance companies, family offices and institutional investors under CISA
- Investment: Equity securities issued by major Swiss companies listed in the SPI 20®
- No investments in securities on the recommendation list for the exclusion of SVVK-ASIR (www.svvk-asir.ch) and controversial weapons.
- Convertible and warrant bonds: none
- Portfolio is passively managed and aims to replicate the gross performance of the benchmark (before fees)
- Securities lending: not permitted
- Use of derivatives: permitted under BVV2
- All investments are subject to market fluctuations. Every fund has specific risks, which can significantly increase under unusual market conditions. Please consult your client advisor for more information on the investment risks of this product.

Securities no. ISIN	4,616,414 CH0046164148
Reuters symbol	_
Bloomberg Ticker	UESWPLX SW
Currency of account	CHF
Issue/redemption	daily
Admin/Custody fees	none
Dilution Levy in Favour of the Fund in/out	0.01%/0.01%
PM fees charged to the NAV	none
TER (as of 31.10.2023)	0.01%
Benchmark	SPI 20 (Total Return)

#### **Current data**

Net asset value 31.5.2024	CHF	3,665.14
– high last 12 months	CHF	3,674.78
<ul> <li>low last 12 months</li> </ul>	CHF	3,119.01
Assets of the unit class in m	CHF	833.87
Fund assets in m	CHF	849.18

# Key risk figures (annualised)

	2 years	3 years
Tracking error	0.02%	0.03%
Beta	1.00	1.00
Correlation	1.00	1.00
Total risk	12.98%	13.12%
Sharpe ratio	0.22	0.30
Risk-free rate (2 years) = $1.03\%$		

The statistical ratios were calculated on the basis of logarithmic returns.


### Sectors (in %)

	Fund	Benchmark
Oil and Gas	0.00	0.00
Basic materials	2.64	2.64
Industrials	15.58	15.58
Consumer goods	26.05	26.05
Health care	34.73	34.75
Consumer services	0.00	0.00
Telecommunications	1.00	0.99
Utilities	0.00	0.00
Financial system	18.85	18.84
Technology	1.15	1.15
Total	100.00	100.00

### Performance (in %)

	Fund	Benchmark
06.2023	0.50	0.50
07.2023	0.19	0.20
08.2023	-1.55	-1.55
09.2023	-1.40	-1.40
10.2023	-5.24	-5.24
11.2023	4.24	4.24
12.2023	2.32	2.32
01.2024	1.72	1.72
02.2024	0.52	0.52
03.2024	3.98	3.99
04.2024	-2.66	-2.66
05.2024	6.84	6.86
2024 YTD	10.57	10.59
2023	5.91	5.96
2022	-14.59	-14.55
2021	23.70	23.70
2020	2.74	2.79
2019	30.59	30.62
Ø p.a. 2 years	3.94	3.99
Ø p.a. 3 years	4.35	4.39
since end of fund launch month		
10.2008	252.75	253.54

#### Indexed performance



Past performance is no guarantee of future trends. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units.

### 10 largest positions according to issuers (in %)

	Fund	Benchmark
Nestle SA	19.99	19.88
Novartis AG	14.95	14.79
Roche Holding AG	12.71	12.69
UBS Group AG	7.21	7.19
ABB	6.26	6.31
Тор 5	61.12	60.86
Cie Financiere Richemont SA	6.06	6.07
Zurich Insurance Group AG	5.43	5.43
Sika AG	3.43	3.51
Holcim	3.35	3.41
Alcon Inc	3.14	3.17
Тор 10	82.53	82.45

For marketing and information purposes by UBS. For professional clients / qualified investors only. UBS funds under Swiss law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Before investing in a product please read the latest prospectus and key information document carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the fund as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underfying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and any to be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The calculated performance takes all costs on the fund level into consideration (ongoing costs). The entry and exit costs, which would have a negative impact on the performance, are not taken into consideration. Investor and which may change in the currency of a financial product or financial service is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions and costs have a negative impact on the investor and which may change in the future. The details and opinions contained in hix accurency in keypectific or future investren

Additional information to investors in specific countries: Switzerland: Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. A summary of investor rights in English can be found online at www.ubs.com/funds. More explanations of financial terms can be found at www.ubs.com/am-glossary. © UBS 2024. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.